Cargando…

EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer

BACKGROUND: Proteolytic enzymes and their regulators have important biological roles in colorectal cancer by stimulating invasion and metastasis, which makes these factors attractive as potential prognostic biomarkers. METHODS: The expression of extracellular matrix metalloproteinase inducer (EMMPRI...

Descripción completa

Detalles Bibliográficos
Autores principales: Boye, K, Nesland, J M, Sandstad, B, Haugland Haugen, M, Mælandsmo, G M, Flatmark, K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419949/
https://www.ncbi.nlm.nih.gov/pubmed/22782346
http://dx.doi.org/10.1038/bjc.2012.293
_version_ 1782240783141699584
author Boye, K
Nesland, J M
Sandstad, B
Haugland Haugen, M
Mælandsmo, G M
Flatmark, K
author_facet Boye, K
Nesland, J M
Sandstad, B
Haugland Haugen, M
Mælandsmo, G M
Flatmark, K
author_sort Boye, K
collection PubMed
description BACKGROUND: Proteolytic enzymes and their regulators have important biological roles in colorectal cancer by stimulating invasion and metastasis, which makes these factors attractive as potential prognostic biomarkers. METHODS: The expression of extracellular matrix metalloproteinase inducer (EMMPRIN) was characterised using immunohistochemistry in primary tumours from a cohort of 277 prospectively recruited colorectal cancer patients, and associations with expression of S100A4, clinicopathological parameters and patient outcome were investigated. RESULTS: One hundred and ninety-eight samples (72%) displayed positive membrane staining of the tumour cells, whereas 10 cases (4%) were borderline positive. EMMPRIN expression was associated with shorter metastasis-free, disease-specific and overall survival in both univariate and multivariate analyses. The prognostic impact was largely confined to TNM stage III, and EMMPRIN-negative stage III patients had an excellent prognosis. Furthermore, EMMPRIN was significantly associated with expression of S100A4, and the combined expression of these biomarkers conferred an even poorer prognosis. However, there was no evidence of direct regulation between the two proteins in the colorectal cancer cell lines HCT116 and SW620 in siRNA knockdown experiments. CONCLUSION: EMMPRIN is a promising prognostic biomarker in colorectal cancer, and our findings suggest that it could be used in the selection of stage III patients for adjuvant therapy.
format Online
Article
Text
id pubmed-3419949
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-34199492013-08-07 EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer Boye, K Nesland, J M Sandstad, B Haugland Haugen, M Mælandsmo, G M Flatmark, K Br J Cancer Molecular Diagnostics BACKGROUND: Proteolytic enzymes and their regulators have important biological roles in colorectal cancer by stimulating invasion and metastasis, which makes these factors attractive as potential prognostic biomarkers. METHODS: The expression of extracellular matrix metalloproteinase inducer (EMMPRIN) was characterised using immunohistochemistry in primary tumours from a cohort of 277 prospectively recruited colorectal cancer patients, and associations with expression of S100A4, clinicopathological parameters and patient outcome were investigated. RESULTS: One hundred and ninety-eight samples (72%) displayed positive membrane staining of the tumour cells, whereas 10 cases (4%) were borderline positive. EMMPRIN expression was associated with shorter metastasis-free, disease-specific and overall survival in both univariate and multivariate analyses. The prognostic impact was largely confined to TNM stage III, and EMMPRIN-negative stage III patients had an excellent prognosis. Furthermore, EMMPRIN was significantly associated with expression of S100A4, and the combined expression of these biomarkers conferred an even poorer prognosis. However, there was no evidence of direct regulation between the two proteins in the colorectal cancer cell lines HCT116 and SW620 in siRNA knockdown experiments. CONCLUSION: EMMPRIN is a promising prognostic biomarker in colorectal cancer, and our findings suggest that it could be used in the selection of stage III patients for adjuvant therapy. Nature Publishing Group 2012-08-07 2012-07-10 /pmc/articles/PMC3419949/ /pubmed/22782346 http://dx.doi.org/10.1038/bjc.2012.293 Text en Copyright © 2012 Cancer Research UK https://creativecommons.org/licenses/by-nc-sa/3.0/From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Molecular Diagnostics
Boye, K
Nesland, J M
Sandstad, B
Haugland Haugen, M
Mælandsmo, G M
Flatmark, K
EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer
title EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer
title_full EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer
title_fullStr EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer
title_full_unstemmed EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer
title_short EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer
title_sort emmprin is associated with s100a4 and predicts patient outcome in colorectal cancer
topic Molecular Diagnostics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419949/
https://www.ncbi.nlm.nih.gov/pubmed/22782346
http://dx.doi.org/10.1038/bjc.2012.293
work_keys_str_mv AT boyek emmprinisassociatedwiths100a4andpredictspatientoutcomeincolorectalcancer
AT neslandjm emmprinisassociatedwiths100a4andpredictspatientoutcomeincolorectalcancer
AT sandstadb emmprinisassociatedwiths100a4andpredictspatientoutcomeincolorectalcancer
AT hauglandhaugenm emmprinisassociatedwiths100a4andpredictspatientoutcomeincolorectalcancer
AT mælandsmogm emmprinisassociatedwiths100a4andpredictspatientoutcomeincolorectalcancer
AT flatmarkk emmprinisassociatedwiths100a4andpredictspatientoutcomeincolorectalcancer